Oops! Something went wrong while submitting the form.
Services
Genetic testing is part of how some connective tissue questions are answered, not all of them. Thirteen subtypes of Ehlers-Danlos syndrome can be confirmed by examining specific genes — including classical and vascular EDS, and a number of rarer subtypes. The genes responsible for hypermobile EDS and the hypermobility spectrum disorders have not yet been identified. Those remain clinical diagnoses, made against the 2017 international criteria.
This means a gene panel can do two useful things, and one thing it cannot. It can confirm a specific heritable subtype where the picture suggests one. It can rule out a serious subtype that needs to be excluded — vascular EDS in particular. It cannot, by itself, confirm hEDS or HSD.
A second part of the work is what the result means for the family. Genetic information is rarely only medical. A pathogenic variant in one person may matter to a sibling, a parent or a child. The counselling sits alongside the testing for that reason.
This service is for people in the connective tissue pathway where genetic testing has a defined clinical role — for example, where a personal or family history suggests a heritable subtype, where features raise concern about a rarer connective tissue disorder, where a known pathogenic variant in a relative makes cascade testing appropriate, or where pregnancy planning needs a clearer picture of inheritance.
A genetic counsellor reviews the personal medical history, family history and the current clinical picture, and discusses what genetic testing can and cannot answer in this case. Where testing is unlikely to add useful information, that is said.
If testing is indicated, a gene panel is selected to match the clinical question, not as a default. The panel size, the conditions covered and the cost are explained before any sample is taken. The sample is collected at home through a kit, and returned to the laboratory.
When the result returns, the genetic counsellor reads it against the rest of the picture: personal history, family history, the symptom pattern already documented in the pathway. A pathogenic variant is one piece of the picture. A negative result also has a meaning, and that meaning is explained, not glossed over.
Where a pathogenic collagen variant is identified, the implications for first-degree relatives are discussed, including the cascade testing biio. is able to offer to eligible family members. The decision about whether and when to involve family is the patient's.
The result is documented in the same record as the rest of the connective tissue work. Where it confirms a subtype, the management implications — surveillance for vascular complications, pregnancy planning, anaesthetic considerations — are linked through to the relevant parts of the care plan. Where it does not identify a variant, the pathway continues with a clinical diagnostic assessment against the 2017 hEDS criteria, where that is appropriate. Genetic information evolves; the counsellor remains available when the patient's circumstances change.
When genetic testing is the right step in this pathway, the outcome is a clearer clinical picture rather than a yes-or-no verdict. A pathogenic variant gives the diagnosis a name and a known biology, and changes what surveillance, family discussion and care planning need to consider. The absence of a variant is also a result — it narrows the differential and clarifies what the rest of the pathway needs to do.
For the family, a result can change what is unknown into something known, in either direction. That is its own kind of clarity, even when the result is unwelcome.
The work does not end at the result. It is the start of a longer conversation about what the result means for daily life, for relatives, and for the rest of the care plan.